GOYA, NCT01287741 / 2010-024194-39: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma |
|
|
| Terminated | 3 | 1418 | Canada, Japan, US, Europe, RoW | Rituximab, MabThera, Rituxan, Obinutuzumab, GA101, RO5072759, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Hoffmann-La Roche, Fondazione Italiana Linfomi ONLUS | Diffuse Large B-Cell Lymphoma | 04/16 | 01/18 | | |
| Terminated | 3 | 671 | Europe | GA101, obinutuzumab, Gazivaro, Rituximab, Mabthera, Doxorubicin, Cyclophosphamide, Prednisone, Bleomycin, Vindesin, Vincristine | The Lymphoma Academic Research Organisation, Hoffmann-La Roche | Diffuse Large B Cell Lymphoma CD20 Positive | 08/16 | 12/17 | | |
STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 270 | Europe, US, RoW | Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin | Hoffmann-La Roche | Diffuse Large B-cell Lymphoma | 04/25 | 04/25 | | |